The "12th Five-Year Plan" major new medicine special anti-lung cancer drug "Kai Mena" follow-up free drug use activities yesterday (9th) was awarded for the designated dispensing point. Sang Guowei, vice chairman of the Standing Committee of the National People's Congress and president of the China Pharmaceutical Industry Development Association, and Ding Xiangyang, deputy mayor of Beijing attended the awarding ceremony.
Since 2007, malignant tumors have been the "first killer" of Beijing citizens' health. The proportion of deaths from malignant tumors to total deaths rose from 20.7% in 2005 to 25.6% in 2010. Among them, lung cancer accounted for 30% of the deaths of malignant tumors, ranking first.
In August 2011, China's first self-developed chemical synthesis small molecular targeted anti-lung cancer new drug “Kemena†was launched. Clinical trials have shown that it has a low incidence of adverse reactions and a more gradual disease progression. Previously, these patients with lung cancer all relied on imported drugs. The listing of “Kamena†reduced patient costs by one-third.
In order to further reduce the burden on patients, under the active coordination of the Beijing Municipal Health Bureau, yesterday, “Kemena†manufacturer Zhejiang Beida Pharmaceutical Co., Ltd. launched the follow-up free drug research “Kami†at Beijing Chest Hospital. Some hospitals will track patients who use Kemena. For patients who have been continuously using Kemeina for 6 months, the doctor has determined that the drug is effective for the condition. After the review, he can receive follow-up treatment medication free of charge at the Jingweida pharmacy near Zizhu Bridge, Xisanhuan, and use it for life free of charge. . (Fang Fang)
Since 2007, malignant tumors have been the "first killer" of Beijing citizens' health. The proportion of deaths from malignant tumors to total deaths rose from 20.7% in 2005 to 25.6% in 2010. Among them, lung cancer accounted for 30% of the deaths of malignant tumors, ranking first.
In August 2011, China's first self-developed chemical synthesis small molecular targeted anti-lung cancer new drug “Kemena†was launched. Clinical trials have shown that it has a low incidence of adverse reactions and a more gradual disease progression. Previously, these patients with lung cancer all relied on imported drugs. The listing of “Kamena†reduced patient costs by one-third.
In order to further reduce the burden on patients, under the active coordination of the Beijing Municipal Health Bureau, yesterday, “Kemena†manufacturer Zhejiang Beida Pharmaceutical Co., Ltd. launched the follow-up free drug research “Kami†at Beijing Chest Hospital. Some hospitals will track patients who use Kemena. For patients who have been continuously using Kemeina for 6 months, the doctor has determined that the drug is effective for the condition. After the review, he can receive follow-up treatment medication free of charge at the Jingweida pharmacy near Zizhu Bridge, Xisanhuan, and use it for life free of charge. . (Fang Fang)
Concentrate Fish Oil,Lemon Flavor Fish Oil,Natural Lemon Fish Oil,Softgel With Fish Gelatin
Weihai Baihe Biology Technological Co., Ltd. , https://www.biohighnutraceutical.com